摘要
目的:该研究旨在观察中药复方芪丹地黄颗粒(QDDHG)对糖尿病并发症的治疗作用。方法:将SD大鼠腹腔注射链脲佐菌素(STZ)诱导成糖尿病模型,实验分为6组(每组n=9),即正常对照组,糖尿病模型组,QDDHG高、中、低剂量组,及阳性药物(氯沙坦)对照组。用氯沙坦或QDDHG治疗4周后,收集血液样品。分别于给药0、2、4、6、8、10周检测血糖和体质量。给药后第10周处死大鼠采血检测其血脂和血清肌酐(Scr)指标。前一天收集大鼠24 h尿液(24U-vol),记录尿量,并检测24 h尿蛋白(24 hU-pro)、内生肌酐清除率(Ccr),取器官进行病理形态学检测。结果:通过QDDHG治疗可显著改善糖尿病大鼠Scr、Ccr,低密度脂蛋白(LDL)及甘油三酯(TG),与正常组比较(P <0. 05)。对24 h U-pro改善尤为明显(P <0. 01),对血糖和体质量则无明显影响。病理结果显示对糖尿病大鼠的改善作用主要在肾脏,对胰腺,心脏和肝脏则没有明显影响。结论:QDDHG具有肾脏保护作用与血脂的调节功能。
Objective:The purpose of this study was to observe the therapeutic effect of Chinese herbal compound Qidan Dihuang Granule( QDDHG) on diabetic complications. Methods:SD rats were intraperitoneally injected with streptozotocin( STZ) to induce diabetes. The experiment was divided into 6 groups( n = 9 in each group),including normal control group,diabetes model group,QDDHG high,medium and low dose groups,and a positive drug( losartan) control group. After 4 weeks treatment with losartan or QDDHG,blood samples were collected. Blood glucose and body weight were measured at 0,2,4,6,8 and 10 weeks,respectively. At the 10 th week after the administration,the rats were sacrificed for blood sampling and serum creatinine( Scr). The rats were collected 24 h urine(24 U-vol) the day before,and the urine volume was recorded. The 24-hour urine protein(24 hU-pro) and endogenous creatinine clearance rate( Ccr) were detected,and the organs were taken out for pathological examination. Results:Scr,Ccr,low-density lipoprotein( LDL) and triglyceride( TG) in diabetic rats were significantly improved by QDDHG treatment compared with the normal group( P < 0. 05). The improvement of 24 h U-pro was especially significant( P <0. 01),while it had no significant effect on blood glucose and body weight. Pathological results showed that the improvement in diabetic rats was mainly in the kidneys,but there was no significant effect on the pancreas,heart or liver. Conclusion:QDDHG has renal protective effect and regulation of blood lipids.
引文
[1] Ogurtsova K,Da Rocha Fernandes JD,Huang Y,et al. IDF Diabetes Atlas:Global estimates for the Drevalence of diabetes for 2015 and2040[J]. Diabetes Res clin Pract,2017,128:40-50.
[2] Xu Y,Wang L,He J,et al. Prevalence and control of diabetes in Chinese adults[J]. JAM A,2013,310(9):948-959
[3] La Vecchia C,Negri E,Decarli A,et al. Diabetes mellitus and the risk of primary liver cancer[J]. Int J Cancer,1997,73(2):204-207.
[4] Breton MD,Patek SD,Lv D,et al. Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus[J]. Diabetes Technol Ther,2018,20(8):531-540.
[5]熊燕,林瑗.糖尿病并发症的研究进展[J].中国医师杂志,2017,19(10):1441-1449.
[6] Zhang K,Pugliese M,Pugliese A. et al. Biological Active Ingredients of Traditional Chinese Herb Astragalus Membranaceus On Treatment of Diabetes:A Systematic Review[J]. Mini Reviews in Medicinal Chemistry,2015,15(4):315-329.
[7] Hou Q,He WJ,Chen L,et al. Effects of the Four-Herb Compound ANBP on Wound Healing Promotion in Diabetic Mice[J]. Int J Low Extrem Wounds,2015,4(4):335-342.
[8]代小雨,邓金华,甘晓辉.传统中药治疗糖尿病肾病机制研究进展[J].中国中西医结合肾病杂志,2017,18(3):270-273.
[9] Tiwari P,Ahmad K,Baig MH. Gymnema Sylvestre for Diabetes:From Traditional Herb to Future S Therapeutic[J]. Current Pharmaceutical Design,2017,23(11):1667-1676.
[10]唐杨,李小生,罗仁,等.循证复方芪丹地黄颗粒治疗糖尿病肾病的临床疗效观察[J].中国现代医生,2016,54(14):136-139.
[11]刘玉.芪丹地黄颗粒对DNⅢ期临床疗效的初步研究[D].广州:南方医科大学,2013.
[12] Xiang L,Jiang P,Zhou L,et al. Additive Effect of Qidan Dihuang Grain,a Traditional Chinese Medicine,and Angiotensin Receptor Blockers on Albuminuria Levels in Patients with Diabetic Nephropathy:A Randomized,Parallel-Controlled Trial[J]. Evid Based Complement Alternat Med,2016,2016:1064924.
[13] Wang Q,Shao X,Xu W,et al. AstragalosidesⅣinhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epitllelial cells[J]. Ren Fail,2014,36(3):400-406.
[14] Dong Z,Chen CX. Effect of catalpol on diabetic nephropathy in rats[J]. Phytomedicine,2013,20(11):1023-1029.
[15] YinD,Yin J,Yang Y,et al. Renoprotection of Danshen Injection on streptozotocin-induced diabetic rats,associated with tubularfunction and structure[J]. J Ethnopharmacol,2014,151(1):667-674.
[16] Masson R M,Wahab N A. Extracellular Matrix Metabolism in Diabetic Nephropathy[J]. Journal of the American Society of Nephrology,2003,14(5):1358-1373.
[17] Whiting D,Guariguata L,Weil C,et al. IDF diabetes atalas:global estimates of the prevalence of diabetes for 2011 and 2030[J]. Diabetes Res Clin Pract,2011,94(2):311-321.
[18]胡荷花.糖尿病及其并发症的临床检验研究[J].中国社区医师,2018,34(2):120-121.
[19] Davison LJ. Diabetes Mellitus and Pancreatitis–Cause Or Effect?[J]. Journal of Small Animal Practice,2015,56(1):50-59.
[20] Hirota M,Shimosegawa T,Masamune A,et al. The Seventh Nationwide Epidemiological Survey for Chronic Pancreatitis in Japan:Clinical Significance of Smoking Habit in Japanese Patients[J]. Pancreatology,2014,14(6):490-496.
[21] Kim D,Choy YS,Park EC. Association Between Secondhand Smoke and Glycemic Control in Adult Diabetes Patients[J]. Preventive Medicine,2017,94:48-54.
[22] Kousathana F,Georgitsi M,Lambadiari V,et al. Defective Production of Interleukin-1 Beta in Patients with Type 2 Diabetes Mellitus:Restoration by Proper Glycemic Control[J]. Cytokine,2017,90:177-184.
[23] Toba H,Mitani TT,Imai N,et al. Inhibition of the Renal Renin-Angiotensin System and Renoprotection by Pitavastatin in Type1 Diabetes[J]. Clinical&Experimental Pharmacology&Physiology,2010,37(11):1064-1070.
[24] Modak M,Dixit P,Londhe J,et al. Indian Herbs and Herbal Drugs Used for the Treatment of Diabetes[J]. Journal of Clinical Biochemistry&Nutrition,2007,40(3):163-173.
[25] Taskinen MR. Controlling Lipid Levels in Diabetes[J]. Acta Diabetologica,2002,39(2):29-34
[26]赵龙,关广聚.糖尿病肾病发病机制研究进展[J].中华肾脏病杂志,2013,29(7):554-557.
[27] El-Serag HB,Tran T,Everhart JE. Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma[J]. Gastroenterology,2004,126(2):460-468.